They also enhance the efficacy of chimeric antigen receptor T cell (CAR-T) therapy by activating the STAT5 signalling pathway, promoting the formation of CD122+/CXCR3+/PD-1 memory T cells, and increasing tumour infiltration through elevated CXCL9/CXCL10 expression. Here, CXCR3 is linked to neoplasm.